Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -238.24% is 146% below its 5-year average of -96.91%, near the low end of its 5-year range (-284.13%–-45.18%).
As of the fiscal period ended Tuesday, June 30, 2026. 56.59% below its 12-month average of -152.15%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -238.24%.
RETURN ON EQUITY (ROE)
-238.24%
RETURN ON EQUITY (ROE) AVG TTM
-152.15%
RETURN ON EQUITY (ROE) AVG 3Y
-119.77%
RETURN ON EQUITY (ROE) AVG 5Y
-96.91%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-56.59%
CURRENT VS 3Y AVG
-98.92%
CURRENT VS 5Y AVG
-145.84%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.09%
median of 523 covered companies
CURRENT VS SECTOR MEDIAN
-494.28%
vs the sector median at left
Aligos Therapeutics, Inc.
Market Cap
$33.51M
Return on Equity (ROE)
-238.24%
TTM Avg
-152.15%
3Y Avg
-119.77%
5Y Avg
-96.91%
Market Cap
$33.35M
Return on Equity (ROE)
N/A
TTM Avg
333.35%
3Y Avg
376.86%
5Y Avg
270.78%
Market Cap
$33.35M
Return on Equity (ROE)
-248.21%
TTM Avg
-991.58%
3Y Avg
-655.25%
5Y Avg
-438.62%
Market Cap
$34.01M
Return on Equity (ROE)
-44.50%
TTM Avg
-16.33%
3Y Avg
-36.34%
5Y Avg
-33.52%
Market Cap
$32.44M
Return on Equity (ROE)
2.91%
TTM Avg
-2.27%
3Y Avg
5.52%
5Y Avg
6.87%
Market Cap
$35.15M
Return on Equity (ROE)
-154.06%
TTM Avg
-1.75%
3Y Avg
68.54%
5Y Avg
60.27%
Market Cap
$35.42M
Return on Equity (ROE)
329.02%
TTM Avg
154.76%
3Y Avg
265.18%
5Y Avg
128.71%
Market Cap
$31.36M
Return on Equity (ROE)
-86.96%
TTM Avg
-27.78%
3Y Avg
5.60%
5Y Avg
57.54%
Market Cap
$31.32M
Return on Equity (ROE)
-120.40%
TTM Avg
-43.89%
3Y Avg
-83.08%
5Y Avg
-65.54%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | $33.51M | -238.24% | -152.15% | -119.77% | -96.91% |
| EUDA Health Holdings Limited (EUDA)vs › | $33.35M | N/A | 333.35% | 376.86% | 270.78% |
| HeartBeam, Inc. (BEAT)vs › | $33.35M | -248.21% | -991.58% | -655.25% | -438.62% |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.01M | -44.50% | -16.33% | -36.34% | -33.52% |
| Nortech Systems Incorporated (NSYS)vs › | $32.44M | 2.91% | -2.27% | 5.52% | 6.87% |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.15M | -154.06% | -1.75% | 68.54% | 60.27% |
| Elutia Inc (ELUT)vs › | $35.42M | 329.02% | 154.76% | 265.18% | 128.71% |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $31.36M | -86.96% | -27.78% | 5.60% | 57.54% |
| Context Therapeutics Inc. (CNTX)vs › | $31.32M | -120.40% | -43.89% | -83.08% | -65.54% |
| MIRA Pharmaceuticals, Inc. (MIRA)vs › | $31.29M | -116.14% | -228.74% | 113.10% | 76.03% |
ROE
-238.2%
ROA
-114.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -238.24% |
| 2026-03-31 | -284.13% |
| 2025-12-31 | -45.18% |
| 2025-09-30 | -120.37% |
| 2025-06-30 | -72.83% |
| 2025-03-31 | -45.74% |
| 2024-09-30 | -153.61% |
| 2024-06-30 | -112.65% |
| 2024-03-31 | -166.54% |
| 2023-12-31 | -95.22% |
| 2023-09-30 | -148.98% |
| 2023-06-30 | -118.12% |
| 2023-03-31 | -98.39% |
| 2022-12-31 | -92.44% |
| 2022-09-30 | -91.69% |
| 2022-06-30 | -92.26% |
| 2022-03-31 | -89.13% |
| 2021-12-31 | -69.47% |
| 2021-09-30 | -57.62% |
| 2021-06-30 | -74.14% |
| 2021-03-31 | -59.52% |
| 2020-12-31 | -49.33% |
| 2020-06-30 | -59.91% |
| 2020-03-31 | -53.14% |
